Antibiotic Drug Articles & Analysis
7 news found
And it is used parenterally and short-term to relieve symptoms of osteoarthritis.D-Glucosamines for Research Use?As a drug delivery company that specializes in a range of formulation and drug delivery technologies, CD Bioparticles now offers a series of D-Glucosamines for research uses, such as CInd™ D-Glucosamine Hydrochloride, CInd™ D-Glucosamine Sulfate·2KCl, ...
Michael Niederman, a leading expert in respiratory infections and a member of N8 Medical’s Scientific Advisory Board stated “Anything that can significantly reduce the presence of pathogens on the surface of an endotracheal tube is a welcome advance that has the potential to reduce a patient’s length of stay, reduce antibiotic and drug use and ...
"Symberix is developing first-in-class adjunctive therapies to mitigate the debilitating lower GI side effects of pain, cancer and organ-transplant medicines by selectively inhibiting β-glucuronidase enzymes in gut bacteria with small-molecule, non-antibiotic drugs,” said Ward Peterson, Ph.D., CEO of Symberix. “Our approach could be as clinically ...
Once identified, the tech developed a resistance profile of the patient’s infection, which told doctors what drugs would work most effectively for each patient. Other than helping patients get the correct treatment more quickly, the technology can also help the medical field reduce the over-prescription of broad-spectrum antibiotics, the study’s ...
Wagoner was the founder and CEO of Icagen, which focused on discovering drugs for hematologic, neurologic, urinary and cardiovascular disorders. ...
The U.S. Food & Drug Administration today released a long pending policy that lays out a voluntary approach to reducing the use of antibiotics in animals that are not sick. ...
Disease emergence also occurs in developed nations due to antibiotic multi-drug resistance, leading to diseases such as extremely drug-resistant TB (XDR TB) and also from centralized food processing, and other technologies. ...